29 September 2020>: Clinical Research
Use of the Gout Impact Scale to Evaluate Quality of Life in Chinese Subjects with Gout: A Cross-Sectional Study
Peidan Yang 12CDE* , Zhixin Chen 23CDE* , Yimin Talia Chen 4EF , Minying Liu 1BF , Mingying Zhang 1BF , Xiangwei Yang 1BF , Changsong Lin 1ADF , Qiang Xu 1ABDEFG*DOI: 10.12659/MSM.925593
Med Sci Monit 2020; 26:e925593
Table 3 Exploratory factor analysis of the Gout Impact Scale.
GIS Item(n=24) | Factor loading | ||||
---|---|---|---|---|---|
1st rotated | 2nd rotated | 3rd rotated | 4th rotated | 5th rotated | |
Gout concern overall | |||||
1.a | 0.047 | 0.185 | 0.136 | 0.045 | |
1.b | 0.072 | 0.131 | 0.070 | 0.037 | |
1.c | 0.230 | 0.248 | 0.045 | −0.098 | |
1.d | 0.186 | 0.268 | 0.054 | −0.086 | |
Gout medication side effects, r | |||||
1.f | 0.011 | 0.286 | −0.040 | −0.165 | |
1.l | 0.064 | 0.480 | −0.107 | −0.083 | |
Unmet gout treatment need, r | |||||
1.j | 0.034 | −0.212 | 0.004 | −0.169 | |
1.m | −0.182 | 0.022 | 0.402 | 0.293 | |
1.n | 0.176 | 0.076 | −0.192 | −0.106 | |
Well being during attack | |||||
2.a | 0.082 | 0.023 | 0.268 | −0.115 | |
2.b | 0.172 | 0.015 | 0.250 | −0.069 | |
2.c | 0.215 | 0.009 | 0.263 | −0.078 | |
2.d | −0.136 | 0.234 | 0.025 | −0.080 | |
3.a | 0.093 | 0.240 | 0.006 | −0.010 | |
3.b | 0.071 | 0.008 | 0.226 | 0.044 | |
3.c | −0.056 | 0.137 | −0.005 | 0.023 | |
3.d | 0.122 | −0.043 | 0.190 | 0.022 | |
3.e | 0.195 | −0.069 | 0.182 | 0.057 | |
3.f | 0.126 | 0.051 | 0.145 | 0.001 | |
3.g | 0.162 | 0.031 | 0.197 | 0.106 | |
Gout concern during attack | |||||
1.g | 0.178 | 0.272 | 0.033 | −0.151 | |
1.h | 0.064 | 0.402 | 0.226 | 0.084 | |
1.i | 0.233 | 0.348 | 0.025 | −0.126 | |
1.k | 0.084 | 0.546 | 0.153 | −0.223 | |
Eigenvalues | 7.70 | 4.12 | 2.35 | 1.40 | 1.26 |
VCR (%) | 32.10 | 17.11 | 9.79 | 5.85 | 5.24 |
CVCR (%) | 32.10 | 49.21 | 59.00 | 64.85 | 70.09 |
GIS consists of 24 items with five subscales. VCR – variance contribution rate; CVCR – cumulative variance contribution rate; GIS – Gout Impact Scale. |